Order €1.000 Shell: LYNX €6,00 / Binck €8,00
Bij DEGIRO: €2,30 (klik voor meer info)





MdxHealth

Beleggen, aandelen kopen in België, informatie, koersen en analyses
de zinker
Forum actieveling
Forum actieveling
Berichten: 878
Lid geworden op: 10 jan 2013 17:11
waarderingen: 632
Contacteer:

Re: MdxHealth

Bericht door de zinker »

(ABM FN) MDxHealth heeft het aantal verkochte testen onder druk zien staan door de corona-pandemie, maar toch wist het diagnosticabedrijf de omzet op te krikken. Dit bleek uit een update over het eerste kwartaal donderdag voorbeurs.
De volumes aan verkochte SelectMDx-testen daalden met 28,0 procent, bij ConfirmMDx kwam er toch nog 3,0 procent bij. MDxHealth wees er onder meer op dat dokters hun patiënten nog moeilijk kunnen zien door de corona-uitbraak. Volgens een onderzoek in Urology Times helpen de testen echter goed om de patiënten op te volgen tijdens deze crisis, stelde het bedrijf.
De omzet van MdxHealth steeg in het eerste kwartaal wel, van 4,7 naar 5,9 miljoen dollar.
De supply chain is verder volgens MDxHealth in orde en de financiële positie van het diagnosticabedrijf wordt nauwgezet opgevolgd.
Toch besloot MDxHealth de outlook voor 2020 in te trekken, vanwege de beperkte zichtbaarheid in de huidige corona-tijden.
Door: ABM Financial News.
charel01 liked last!





Volg Beursig.com op Twitter en Facebook

     


Stefkamielkafkajr
Forum actieveling
Forum actieveling
Berichten: 671
Lid geworden op: 25 dec 2013 21:48
waarderingen: 214
Contacteer:

Re: MdxHealth

Bericht door Stefkamielkafkajr »

MDxHealth schrapt jaarprognose
MDxHealth MDXH0,00% , de Amerikaans-Belgische ontwikkelaar van prostaatkankertests, trekt zijn jaarprognose in wegens het coronavirus. In het eerste kwartaal steeg de omzet met 24 procent tot 5,9 miljoen dollar. De verkoop van ConfirmMDx ging 3 procent hoger, die van SelectMDx zakte met 28 procent, vooral omdat de verkopers sinds maart geen artsen meer mogen bezoeken, blijkt uit een persbericht.
Altice europe,aegon,, euronav, exmar , acacia pharma,fagron,,transgene, greenyard ,mdxhealt, pharming, , econocom.Xfab.oxurion.sorrento therapeutics

Gebruikersavatar
Banner
Premiummember
Premiummember
Berichten: 1961
Lid geworden op: 19 feb 2015 09:29
waarderingen: 1154
Contacteer:

Re: MdxHealth

Bericht door Banner »

PRESS RELEASE REGULATED INFORMATION

IRVINE, CA, and HERSTAL, BELGIUM – April 9, 2020 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today provided a business update for the first quarter ended March 31, 2020.


Michael McGarrity, CEO of MDxHealth, commented: “As communicated at the time of our annual results in February, we have been highly focused on the execution of our growth strategy, and our first quarter 2020 results reflect that focus. Product revenues in the first quarter of 2020 increased by 26% compared to Q1-2019 and ConfirmMDx units, while impacted in March by the COVID-19 outbreak, were still up 3% from the same period last year. Despite the unavoidable challenges presented by this pandemic, MDxHealth’s compelling value proposition, strong business fundamentals and emphasis on focus and execution remains unchanged. I would also like to communicate with confidence the following:

Our menu of tests to improve the diagnosis and treatment of patients suspected of prostate cancer remains best-in-class
Our supply chain is in good order and we have taken appropriate measures to ensure the safety and continuity of our laboratory operations
We are committed to prudent financial stewardship and operating discipline
“From a commercial perspective, MDxHealth representative contact with clinicians began to decline in March due to the COVID-19 crisis, predominately affecting SelectMDx volumes. However, the impact of this reduction in volume had minimal effect on our revenues or cash flows given that SelectMDx is not yet reimbursed.

“From the physicians’ perspective, one of the major healthcare effects of the COVID-19 crisis has been their inability to see their patients. However, a recent article published in the Urology Times1 highlighted how the ConfirmMDx test, which can be ordered without a patient visit, helps urologists manage their patients during this unprecedented pandemic. Additionally, it points to ConfirmMDx’s ability to help stratify those patients at very low risk for aggressive prostate cancer who can avoid an office follow up visit, MRI or a prostate biopsy. This is especially important for patients over the age of 65 who are considered high-risk for COVID-19 and who comprise approximately 70% of a urologist’s patient population. MDxHealth is geared to support these urologists and help them navigate these times.

“Our top priority has been to protect our people and their families, as well as our customers and their patients. Our MDxHealth team has adapted to the current challenges and we remain committed to building value for all of our stakeholders, patients, customers, employees and shareholders.”

Highlights for the first quarter ended March 31, 2020

Total revenue of $5.9 million, up 24% from $4.7 million in Q1-2019
Product revenues of $5.6 million, up 26% from $4.5 million in Q1-2019
Growth of 3% in ConfirmMDx units compared to Q1-2019
Reduction of 28% in SelectMDx units compared to Q1-2019


Summary of billable test volume by product

Territory Products Quarter Ended March 31,
2020 2019 % Change
U.S. ConfirmMDx 4,532 4,379 3%
SelectMDx 3,346 4,941 (32)%
E.U. SelectMDx 1,063 1,165 (9)%
COVID-19 and Outlook for 2020

The Company remains confident in the potential of its two complementary commercial stage products to provide urologists with a clear clinical pathway to accurately identify clinically significant prostate cancer, while minimizing the use of invasive procedures. We believe this clinical pathway, with SelectMDx guiding cancer detection in a pre-biopsy setting and ConfirmMDx in a post-biopsy setting, will continue driving momentum and increase market share on all fronts.

As a result of the COVID-19 global pandemic, the Company is suspending its 2020 guidance previously provided on February 26, 2020 as part of its 2019 year-end press release. Current market conditions and rapid developments on the COVID-19 front make it extremely difficult to project future results. The Company has taken the necessary measures to ensure continued ability to provide its services to patients and physicians, while maintaining fiscal responsibility and keeping its employees safe.

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company’s European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

MDxHealth

info@mdxhealth.com

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, and SelectMDx are trademarks or registered trademarks of MDxHealth SA.

1 Urology and Precision Medicine in the COVID-19 Era, by Neal D. Shore, MD, March 27, 2020
https://www.urologytimes.com/coronaviru ... vid-19-era
de zinker liked last!

Gebruikersavatar
ringoeur
Forum veteraan
Forum veteraan
Berichten: 1259
Lid geworden op: 25 jun 2013 11:07
waarderingen: 983
Contacteer:

Re: MdxHealth

Bericht door ringoeur »

10:50 de tijd
Degroof laat koersdoel MDxHealth zakken
De markt heeft vandaag maar weinig zicht op belangrijke verkoopcijfers als het herbestelritme, de volume- en de omzetgroei, zegt Thomas Guillot van Degroof Petercam. Zijn visie wordt bevestigd door het feit dat MDxHealth de jaarprognose intrekt.

In afwachting van een nieuwe kwantitatieve prognose en een update over de (financiële) situatie van het bedrijf handhaaft hij zijn ‘houden’-advies. Hij verlaagt zijn verkoopverwachting voor beide prostaatkankertesten voor dit jaar en laat zijn koersdoel zakken van 1,1 tot 0,8 euro.

Putbruy
Forum elite
Forum elite
Berichten: 4267
Lid geworden op: 18 jul 2013 12:19
waarderingen: 1143
Contacteer:

Re: MdxHealth

Bericht door Putbruy »

het zag er ooit goed uit, jammer dat dit bedrijf een outdated randfenomeen in geworden, gaat ergens in faling of overgenomen worden aan een miniscuul bedrag, mijn gedacht
in port : vanalles..

bertje
Forum elite
Forum elite
Berichten: 6060
Lid geworden op: 30 jul 2012 14:53
waarderingen: 1300
Contacteer:

Re: MdxHealth

Bericht door bertje »

lijkt toch 2de adem gevonden te hebben.

0.78 + 0.1 (14.71%)

al staan we natuurlijk nog nergens.

Gebruikersavatar
ringoeur
Forum veteraan
Forum veteraan
Berichten: 1259
Lid geworden op: 25 jun 2013 11:07
waarderingen: 983
Contacteer:

Re: MdxHealth

Bericht door ringoeur »

20/04/2020 7:24:12
MDxHealth krijgt loonhulp in VS

(ABM FN) Het Amerikaanse dochterbedrijf van MDxHealth krijgt vanwege de corona-uitbraak hulp bij het betalen van de salarissen. Dit meldde MDxHealth maandagochtend.

Onder het Paycheck Protection Program kan MDxHealth een bedrag van 2,3 miljoen dollar tegemoet zien, zodat het de salarissen van zijn werknemers tijdens de corona-uitbraak kan betalen.

Deze lening heeft een looptijd van twee jaar tegen een rente van 1,0 procent per jaar.

Door: ABM Financial News.

de zinker
Forum actieveling
Forum actieveling
Berichten: 878
Lid geworden op: 10 jan 2013 17:11
waarderingen: 632
Contacteer:

Re: MdxHealth

Bericht door de zinker »

Press release
Regulated information – Inside information
IRVINE, CA, and HERSTAL, BELGIUM – 27 April 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth") a commercial-stage innovative molecular diagnostics company, announces today that it entered into a subscription agreement with MVM V LP and MVM GP (No.5) LP, funds managed by MVM Partners LLP (collectively "MVM"), pursuant to which MVM has agreed to provide an equity investment to the Company for an aggregate amount of EUR 12,738,632.94 (or approximately $14 Million).
The equity investment will consist of a subscription of 20,162,924 new ordinary shares of the Company at an issue price of EUR 0.632 per share, representing a 5% discount to the 45-day volume weighted average price. As a result of the transaction, MVM will become a 22% shareholder of the Company. The transaction is subject to limited customary conditions precedent and is expected to close on or about 15 May 2020.
The net proceeds of the capital increase will be used to support the Company's growth strategy, as well as for general corporate purposes.
As part of the equity investment, MVM will be entitled to have one observer at the board of directors of the Company as from today and, subject to completion of the transaction, for as long as MVM will hold in aggregate 5% of the Company's outstanding shares. In addition, the Company agreed that it will propose to the Company's general shareholders' meeting to appoint Eric Bednarski, PhD, as director of the Company. Kyle Dempsey, MD, shall be an observer to the board.
Michael McGarrity, CEO of MDxHealth, commented: "We are very excited to have this infusion of growth capital into MDxHealth. MVM represents the highest quality of healthcare investors. This investment marks a validation milestone for the Company and signals recognition of our value proposition in both the European and U.S. markets. On behalf of MDxHealth, we would like to welcome Eric Bednarski and MVM to our team and look forward to building value for all our stakeholders including patients, customers, employees and shareholders."
Eric Bednarski, Partner of MVM, commented: “Prostate cancer continues to be the second leading cause of cancer death among men and there remains a great need to improve diagnosis and treatment. MDxHealth is a rare example of a company with strong leadership and best-in-class diagnostic tests which provide meaningful and necessary information to better inform physicians and patients. We are excited to partner with MDxHealth and are pleased that this funding will provide support for the growth of its ConfirmMDx and SelectMDx tests.”
Koen Hoffman, Chairman of the Board of Directors of MDxHealth commented: “On behalf of the Board of Directors, I would like to welcome Eric Bednarski and the MVM team as partners to MDxHealth. We have been very impressed with their diligence and professionalism, and we believe they bring a deep understanding of our business and will complement our Board and Management team as we build value in MDxHealth.”
The new shares to be issued will have the same rights and benefits as, and rank pari passu in all respects with, the existing and outstanding shares of the Company at the moment of their issuance and will be entitled to distributions in respect of which the relevant record date or due date falls on or after the date of issue of the new shares. The Company shall apply to Euronext Brussels for the admission to trading of the new shares as soon as practicable, and in any event within 90 days after their issuance.
charel01 liked last!

Gebruikersavatar
wimvd
Premiummember
Premiummember
Berichten: 3405
Lid geworden op: 15 feb 2013 12:40
waarderingen: 766
Contacteer:

Re: MdxHealth

Bericht door wimvd »

Ai ai, verwatering van de bestaande aandeelhouder aan quasi de laagste koers. Jaren geleden dit bedrijf nog eens grondig bestudeerd en toen stapte ik in aan 2,3 EUR, intussen al een hele tijd eruit toen CEO Groen nooit woord hield. Jammer dat we nooit de echte toedracht zullen kennen waarom de verkopen in de US nooit op gang kwamen in vergelijking met de sales kosten. Daarbovenop gaven ze hun kroonjuwelen dan ook nog weg aan een grotere pharma-speler. Zo zie je maar dat niet alle biotech-aandelen in België een succesverhaal zijn. R.I.P.
Solvay (71,21), EVS (12,82), Ageas (31,42), Aperam (20,09), Wereldhave BE (50,8), Intervest (21,32), Proximus (18,19), Boskalis (16,05), Campine (26), GIMV (51,1), Euronav (8,24), Ontex (12,9), Retail Estates (61,05)

Gebruikersavatar
Gauthier
Premiummember
Premiummember
Berichten: 130
Lid geworden op: 17 jan 2015 15:44
waarderingen: 119
Contacteer:

Re: MdxHealth

Bericht door Gauthier »

Daar is de langverwachte kapitaalverhoging bij MDxHealth dan. Life Sciences investeerder MVM Partners wordt
de grootste aandeelhouder met een belang van 22%, naast Valiance AM (16%) en Biovest (14%), door de
intekening op 20,2 miljoen aandelen aan 0,632 euro per aandeel (5% korting op de gemiddelde koers van de
voorbije 45 dagen). De investering van 12,7 miljoen euro spekt de kasreserves aanzienlijk (eerder al werd getankt
via het Paycheck Protection Program in de VS). KBCS meent dat deze zeer geloofwaardige, praktijkgerichte en
gespecialiseerde investeerder in biowetenschappen goed nieuws voor de groep is, die nu naar schatting 32
miljoen dollar cash heeft en verder kan tot midden 2021. Koersdoel van 0,9 euro en “Houden”-advies blijven
behouden
Cash: 23%
ETF: 43% (IWDA, USTE, IEMA, IUSN, WHEA)
Stocks: 34% (AGES, ASMI, BABA, BPOST, EUAV, FB, GBLB, GLPG, GOOG, PRX, SOF)

Deelnemen aan het forum + meer functies?

Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!


Plaats reactie